Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model
暂无分享,去创建一个
A. Eggermont | J. D. de Wilt | B. van Etten | S. V. van Tiel | T. L. T. ten Hagen | Marc G. A van Ijken | Sandra T van Tiel | M. G. V. van Ijken
[1] M. Oudkerk,et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. , 2000, Hepato-gastroenterology.
[2] A. Eggermont,et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.
[3] A. Eggermont,et al. TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.
[4] I. B. Borel Rinkes,et al. Acute‐phase response patterns in isolated hepatic perfusion with tumour necrosis factor α (TNF‐α) and melphalan in patients with colorectal liver metastases , 1999 .
[5] T. Scherstén,et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] A. Eggermont,et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.
[7] A. Eggermont,et al. In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats , 1999, British Journal of Cancer.
[8] A. Eggermont,et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.
[9] H. Alexander,et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] P. Flemming,et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. , 1998, Surgery.
[11] K. Tracey,et al. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] P. Kuppen,et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? , 1998, Seminars in surgical oncology.
[13] D. Fraker,et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Bieler,et al. Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.
[15] G. Bieler,et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. , 1998, Nature medicine.
[16] I. B. Borel Rinkes,et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[17] I. B. Borel Rinkes,et al. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. , 1997, British Journal of Cancer.
[18] I. B. Borel Rinkes,et al. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. , 1997, British Journal of Cancer.
[19] C. Wiltschke,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[21] A. Eggermont,et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.
[22] A. Eggermont,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Eggermont,et al. Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.
[24] K. Tracey,et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone , 1996, The Journal of experimental medicine.
[25] M. Buyse. Meta-analysis group in cancer: reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer , 1996 .
[26] A. Eggermont,et al. VWF release and platelet aggregation in human melanoma after perfusion with TNFα , 1995, The Journal of pathology.
[27] D. Fraker,et al. Use of tumor necrosis factor in isolated hepatic perfusion. , 1994, Circulatory shock.
[28] A. Bengtsson,et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. , 1994, Surgical oncology.
[29] A. Eggermont,et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.
[30] H. Northoff,et al. Production of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the perfused rat liver. , 1993, European cytokine network.
[31] P. Rougier,et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S D Prionas,et al. Dual role of tumor necrosis factor-alpha in angiogenesis. , 1992, The American journal of pathology.
[33] N. Renard,et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Kuppen,et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. , 1991, British Journal of Cancer.
[35] W. Buurman,et al. Evaluation of measurement of human TNF in plasma by ELISA. , 1991, Lymphokine and cytokine research.
[36] C. V. D. van de Velde,et al. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. , 1991, Cancer research.
[37] P. Kuppen,et al. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. , 1990, British Journal of Cancer.
[38] P D Schneider,et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. , 1987, Annals of surgery.
[39] D. Newell,et al. In pursuit of evidence based integrated care , 1987, British Journal of Cancer.
[40] M. Rosenblum,et al. Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.
[41] C. V. D. van de Velde,et al. A successful technique of in vivo isolated liver perfusion in pigs. , 1986, The Journal of surgical research.
[42] M. E. Carver,et al. Serum-free in vitro bioassay for the detection of tumor necrosis factor. , 1986, Journal of immunological methods.
[43] E. Quebbeman,et al. Tumoricidal effects and patient survival after hyperthermic liver perfusion. , 1986, Archives of surgery.
[44] W. Lierse,et al. Vaskularisation von Lebermetastasen: eine korrosionsanatomische Studie , 1986 .
[45] U. Almagro,et al. A technique for isolation perfusion of the canine liver with survival. , 1983, The Journal of surgical research.
[46] J. Tonn,et al. [Isolated liver perfusion with 5-fluorouracil (5-FU) in the human]. , 1982, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[47] D. Levin,et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. , 1978, Cancer research.